摘要
头颈部鳞状细胞癌(HNSCC)是世界上排名第六的最常见的癌症,在过去几十年间,其生存率并没有得到改善。目前的治疗手段包括手术、放射治疗和化疗,但是这些治疗手段对于复发或转移性肿瘤来说都是相对无效的。因此,寻找一种专门针对顽固HNSCC肿瘤干细胞(CSCs)的新型治疗手段迫在眉睫,CSCs是引起肿瘤初发和转移的族群。鉴于其对基因表达和生物进程的巨大影响,包括干细胞功能,非编码RNAs已经成为一种有前景的作为潜在的诊断和治疗靶点的基因研究的新课题。这篇综述对当前的调查研究进行了一个综合的概述,其将有助于我们了解在ncRNA和HNSCC肿瘤干细胞的生物学间的仍然停留在试验阶段的联系。我们这样做的目的是分析干细胞在HNSCC分子靶向癌症治疗的发展过程中的潜在的与干细胞相关的ncRNAs的作用。尽管大多数关于HNSCC和ncRNAD的现代化的知识主要集中于微小核糖核酸,我们仍然选择给予ncRNAs的其他种类(lncRNA、piRNA和 snoRNA)相当的关注,这些其他种类中的许多尚未被很好的了解或还没有被发现,从而代表了在HNSCC治疗中分子靶点或者生物标记的一个潜在的令人兴奋的而尚未被开发的宝库。
关键词: 肿瘤干细胞,头颈部鳞状细胞癌(HNSCC)
图形摘要
Current Drug Targets
Title:Evaluation of Non-Coding RNAs as Potential Targets in Head and Neck Squamous Cell Carcinoma Cancer Stem Cells
Volume: 15 Issue: 13
Author(s): Elham Rahimy, Selena Z. Kuo and Weg M. Ongkeko
Affiliation:
关键词: 肿瘤干细胞,头颈部鳞状细胞癌(HNSCC)
摘要: Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer in the world and has not seen improved survival rates over the past few decades. Current treatment plans include surgery, radiation therapy, and chemotherapy, but these are relatively ineffective options for recurrent or metastatic tumors. Therefore, there is a high priority for new therapies that specifically target the resistant HNSCC cancer stem cells (CSCs), a subpopulation responsible for tumor initiation and metastasis. Given their vast effects on gene expression and biological processes, including stem cell capabilities, non-coding RNAs (ncRNAs) have become a promising new repertoire of genes to investigate as potential diagnostic or therapeutic targets. This review presents a comprehensive overview of current investigative studies that can contribute to our understanding of the still tentative link between ncRNA and the biology of HNSCC cancer stem cells. In doing so, we aim to analyze the potential role of stem cell-related ncRNAs in the development of molecularly targeted cancer therapy for HNSCC. Although the majority of updated knowledge on HNSCC and ncRNA focuses heavily on microRNA, we chose to give considerable attention to the promise of other classes of ncRNAs (lncRNA, piRNA, and snoRNA), many of which are not yet well characterized or are yet to be discovered, and thus represent a potentially exciting and untapped pool of molecular targets or biomarkers in HNSCC therapy.
Export Options
About this article
Cite this article as:
Elham Rahimy, Selena Z. Kuo and Ongkeko M. Weg, Evaluation of Non-Coding RNAs as Potential Targets in Head and Neck Squamous Cell Carcinoma Cancer Stem Cells, Current Drug Targets 2014; 15 (13) . https://dx.doi.org/10.2174/1389450115666141024113446
DOI https://dx.doi.org/10.2174/1389450115666141024113446 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Role of Liprins in the Regulation of Tumor Cell Motility and Invasion
Current Cancer Drug Targets Recent Advances in Superparamagnetic Iron Oxide Nanoparticles for Cellular Imaging and Targeted Therapy Research
Current Pharmaceutical Design Potential and Cytotoxicity of cis-Platinum Complex with Anti-tumor Activity in Combination Therapy
Recent Patents on Anti-Cancer Drug Discovery Dynamic Changes in Phenotypic Groups in Patients with Stable Angina Pectoris after Treatment with Xinxuekang Capsule: A Randomized Controlled Trial
Current Vascular Pharmacology Targeting Epithelial-Mesenchymal Transition Phenotype for Gastro-Intestinal Cancer
Current Pharmaceutical Design Phenolic Compounds in Prevention and Treatment of Skin Cancers: A Review
Current Medicinal Chemistry The VHL Tumor Suppressor: Master Regulator of HIF
Current Pharmaceutical Design ETS Proteins and MMPs: Partners in Invasion and Metastasis
Current Drug Targets The Role of a Human Hematopoietic Mesenchymal Progenitor in Wound Healing and Fibrotic Diseases and Implications for Therapy
Current Stem Cell Research & Therapy Patent Selections:
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Abatacept and Glomerular Diseases: The Open Road for the Second Signal as a New Target is Settled Down
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Saccharomyces Cerevisiae as a Genetic Model in Anticancer Therapy
Current Pharmacogenomics Thermosensitive Liposomes in Cancer Therapy
Recent Patents on Biomedical Engineering (Discontinued) Review of Selected Patents for Cancer Therapy Targeting Tumor Angiogenesis
Recent Patents on Anti-Cancer Drug Discovery Modulation of MicroRNAs by <i>Euphorbia Microsciadia</i> Boiss in MDA-MB-231 Cell Line: New Possibilities in Breast Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery DLEU2: A Meaningful Long Noncoding RNA in Oncogenesis
Current Pharmaceutical Design Cancer Regulator MicroRNA: Potential Relevance in Diagnosis, Prognosis and Treatment of Cancer
Current Medicinal Chemistry MiRNA, a New Treatment Strategy for Pulmonary Fibrosis
Current Drug Targets Resveratrol, a Phytochemical Inducer of Multiple Cell Death Pathways: Apoptosis, Autophagy and Mitotic Catastrophe
Current Medicinal Chemistry A Squamous Cell Gallbladder Carcinoma: A Case Report and Literature Review
New Emirates Medical Journal